Providence Capital Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.69M | Sell |
166,979
-925
| -0.6% | -$24.6K | 0.77% | 56 |
|
|
2025
Q4 | $4.18M | Buy |
167,904
+5,611
| +3% | +$141K | 0.7% | 59 |
|
|
2025
Q3 | $4.14M | Buy |
162,293
+4,488
| +3% | +$111K | 0.72% | 53 |
|
|
2025
Q2 | $3.83M | Buy |
157,805
+42,012
| +36% | +$980K | 0.7% | 56 |
|
|
2025
Q1 | $2.93M | Buy |
115,793
+1,435
| +1% | +$37.5K | 0.61% | 70 |
|
|
2024
Q4 | $3.03M | Buy |
114,358
+409
| +0.4% | +$11.1K | 0.62% | 65 |
|
|
2024
Q3 | $3.3M | Buy |
113,949
+806
| +0.7% | +$23.5K | 0.65% | 65 |
|
|
2024
Q2 | $3.17M | Buy |
113,143
+1,855
| +2% | +$51.1K | 0.69% | 59 |
|
|
2024
Q1 | $3.09M | Buy |
111,288
+29,379
| +36% | +$815K | 0.67% | 63 |
|
|
2023
Q4 | $2.36M | Sell |
81,909
-4,637
| -5% | -$140K | 0.57% | 70 |
|
|
2023
Q3 | $2.87M | Sell |
86,546
-64,466
| -43% | -$2.28M | 0.75% | 60 |
|
|
2023
Q2 | $5.54M | Buy |
151,012
+900
| +0.6% | +$35K | 1.41% | 21 |
|
|
2023
Q1 | $6.12M | Buy |
150,112
+3,148
| +2% | +$136K | 1.62% | 8 |
|
|
2022
Q4 | $7.53M | Buy |
146,964
+1,215
| +0.8% | +$58.3K | 2.03% | 5 |
|
|
2022
Q3 | $6.38M | Buy |
145,749
+360
| +0.2% | +$17.5K | 1.91% | 5 |
|
|
2022
Q2 | $7.62M | Sell |
145,389
-16,358
| -10% | -$834K | 2.22% | 4 |
|
|
2022
Q1 | $8.36M | Buy |
161,747
+10,996
| +7% | +$571K | 2.05% | 5 |
|
|
2021
Q4 | $8.9M | Sell |
150,751
-7,914
| -5% | -$392K | 2.45% | 4 |
|
|
2021
Q3 | $6.82M | Buy |
158,665
+9,987
| +7% | +$442K | 2.13% | 7 |
|
|
2021
Q2 | $5.82M | Buy |
148,678
+4,078
| +3% | +$159K | 1.88% | 11 |
|
|
2021
Q1 | $5.24M | Sell |
144,600
-887
| -0.6% | -$31.5K | 1.9% | 8 |
|
|
2020
Q4 | $5.36M | Buy |
145,487
+10,510
| +8% | +$386K | 2.19% | 5 |
|
|
2020
Q3 | $4.7M | Buy |
134,977
+351
| +0.3% | +$12.3K | 2.48% | 7 |
|
|
2020
Q2 | $4.18M | Sell |
134,626
-2,317
| -2% | -$78.7K | 2.37% | 6 |
|
|
2020
Q1 | $4.24M | Buy |
136,943
+39,148
| +40% | +$1.33M | 2.55% | 6 |
|
|
2019
Q4 | $3.63M | Buy |
97,795
+1,076
| +1% | +$38.3K | 1.95% | 7 |
|
|
2019
Q3 | $3.3M | Buy |
96,719
+14,988
| +18% | +$545K | 1.94% | 6 |
|
|
2019
Q2 | $3.36M | Buy |
81,731
+2,368
| +3% | +$94K | 1.99% | 6 |
|
|
2019
Q1 | $3.2M | Buy |
79,363
+1,619
| +2% | +$64.8K | 2.01% | 5 |
|
|
2018
Q4 | $3.22M | Sell |
77,744
-10,414
| -12% | -$432K | 2.21% | 4 |
|
|
2018
Q3 | $3.69M | Sell |
88,158
-12,616
| -13% | -$486K | 2.41% | 4 |
|
|
2018
Q2 | $3.47M | Buy |
100,774
+3,648
| +4% | +$125K | 2.43% | 4 |
|
|
2018
Q1 | $3.27M | Buy |
97,126
+5,248
| +6% | +$180K | 2.45% | 3 |
|
|
2017
Q4 | $3.16M | Buy |
+91,878
| New | +$3.13M | 2.44% | 4 |
|
Other funds holding PFE
VCM
VPM
Providence Capital Advisors's PFE Position: Q1 2026 in Review
Providence Capital Advisors reduced its Pfizer (PFE) stake by 0.55% in Q1 2026, selling an estimated $24.6K and leaving 166,979 shares worth $4.69M. The position accounts for 0.77% of the portfolio, ranked #56.
Providence Capital Advisors first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $8.9M in Q4 2021. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Providence Capital Advisors held 166,979 shares of Pfizer worth $4.69M as of Q1 2026.
- Providence Capital Advisors sold 925 Pfizer shares in Q1 2026, an estimated $24.6K.
- Pfizer made up 0.77% of Providence Capital Advisors's portfolio in Q1 2026, its #56 holding.
- Providence Capital Advisors first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- Providence Capital Advisors's Pfizer position peaked at $8.9M in Q4 2021.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Providence Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.